Comparative efficacy of once-weekly semaglutide and SGLT-2 inhibitors in type 2 diabetic patients inadequately controlled with metformin monotherapy: a systematic literature review and network meta-analysis.

Sharma R, Wilkinson L, Vrazic H, Popoff E, Lopes S, Kanters S, Druyts E

Current medical research and opinion29 May 2018Cited by 24 (Europe PMC)

PMID29764222DOI10.1080/03007995.2018.1476332PepBankPUB-29764222

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes inadequately controlled on metformin, once-weekly semaglutide 1.0 mg lowered HbA1c more than each SGLT-2 inhibitor.
In plain wordsIn adults with type 2 diabetes on metformin, semaglutide 1.0 mg lowered HbA1c more than SGLT-2 inhibitor drugs.
Peptide
Semaglutide
Outcome
DecreaseHbA1c change versus SGLT-2 inhibitors
Study
n: not reported in source
Comparator
SGLT-2 inhibitors
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.0 mg once weekly · 26 (+/-4) weeksAs given in this study (human).
Measurements
Mean difference in HbA1c change
−0.66%
vs canagliflozin 300 mg
Mean difference in HbA1c change
−1.11%
vs dapagliflozin 5 mg
Source sentences
Summary
The mean differences in change from baseline in HbA_1c for once-weekly semaglutide 1.0 mg vs SGLT-2is ranged from -0.66% for canagliflozin 300 mg (95% Credible Intervals [CrI]: -0.82, -0.50%) to -1.11% for dapagliflozin 5 mg (95% CrI: -1.37, -0.85%).
1 context sentence(design, population, supporting numbers)
Summary · context
The present network meta-analysis (NMA) evaluated comparative efficacy and safety of once-weekly semaglutide and sodium-glucose co-transporter 2 inhibitors (SGLT-2is) in T2D patients inadequately controlled with metformin.
Report a problemFND-2976422201
02HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes inadequately controlled on metformin, once-weekly semaglutide 0.5 mg lowered HbA1c more than SGLT-2 inhibitors.
In plain wordsIn adults with type 2 diabetes on metformin, semaglutide 0.5 mg lowered HbA1c more than SGLT-2 inhibitor drugs.
Peptide
Semaglutide
Outcome
DecreaseHbA1c change versus SGLT-2 inhibitors
Study
n: not reported in source
Comparator
SGLT-2 inhibitors
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.5 mg once weekly · 26 (+/-4) weeksAs given in this study (human).
Source sentences
Summary
Statistically significant reductions in HbA1c were observed with both 1.0 mg and 0.5 mg doses of once-weekly semaglutide when compared to SGLT-2is.
1 context sentence(design, population, supporting numbers)
Summary · context
The present network meta-analysis (NMA) evaluated comparative efficacy and safety of once-weekly semaglutide and sodium-glucose co-transporter 2 inhibitors (SGLT-2is) in T2D patients inadequately controlled with metformin.
Report a problemFND-2976422202
03HumanSystematic reviewEfficacy outcome
Semaglutide 1.0 mg reduced weight significantly more than all SGLT-2 inhibitors of interest in adults with type 2 diabetes on metformin.
In plain wordsSemaglutide 1.0 mg lowered weight more than SGLT-2 inhibitor drugs in adults with type 2 diabetes on metformin.
Peptide
Semaglutide
Outcome
DecreaseWeight change versus SGLT-2 inhibitors
Study
n: not reported in source
Comparator
SGLT-2 inhibitors
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Studied dose
1.0 mg once weekly · 26 (+/-4) weeksAs given in this study (human).
Source sentences
Summary
Once-weekly semaglutide 1.0 mg performed significantly better than all SGLT-2is of interest in reducing weight
1 context sentence(design, population, supporting numbers)
Summary · context
The present network meta-analysis (NMA) evaluated comparative efficacy and safety of once-weekly semaglutide and sodium-glucose co-transporter 2 inhibitors (SGLT-2is) in T2D patients inadequately controlled with metformin.
Report a problemFND-2976422203
04HumanSystematic reviewEfficacy outcome
Semaglutide 1.0 mg improved fasting plasma glucose significantly more than all SGLT-2 inhibitors of interest in adults with type 2 diabetes on metformin.
In plain wordsSemaglutide 1.0 mg improved fasting blood glucose more than SGLT-2 inhibitor drugs in adults with type 2 diabetes on metformin.
Peptide
Semaglutide
Outcome
DecreaseFasting plasma glucose versus SGLT-2 inhibitors
Study
n: not reported in source
Comparator
SGLT-2 inhibitors
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.0 mg once weekly · 26 (+/-4) weeksAs given in this study (human).
Source sentences
Summary
Once-weekly semaglutide 1.0 mg performed significantly better than all SGLT-2is of interest in reducing weight and improving FPG levels
1 context sentence(design, population, supporting numbers)
Summary · context
The present network meta-analysis (NMA) evaluated comparative efficacy and safety of once-weekly semaglutide and sodium-glucose co-transporter 2 inhibitors (SGLT-2is) in T2D patients inadequately controlled with metformin.
Report a problemFND-2976422204
05HumanSystematic reviewEfficacy outcome
Systolic blood pressure reduction with semaglutide 1.0 mg was not statistically distinguishable from that with SGLT-2 inhibitors.
In plain wordsSemaglutide 1.0 mg and SGLT-2 inhibitor drugs lowered systolic blood pressure by amounts that could not be told apart statistically.
Peptide
Semaglutide
Outcome
No significant changeSystolic blood pressure versus SGLT-2 inhibitors
Study
n: not reported in source
Comparator
SGLT-2 inhibitors
Analysis
Primary
Outcome group
Blood pressure · Cardiovascular
Studied dose
1.0 mg once weekly · 26 (+/-4) weeksAs given in this study (human).
Source sentences
Summary
however, SBP reduction was not statistically differentiable
1 context sentence(design, population, supporting numbers)
Summary · context
The present network meta-analysis (NMA) evaluated comparative efficacy and safety of once-weekly semaglutide and sodium-glucose co-transporter 2 inhibitors (SGLT-2is) in T2D patients inadequately controlled with metformin.
Report a problemFND-2976422205

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 2 completed · 2 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT02648204

Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes.

Novo Nordisk A/Sn = 1,2016 Jan 2016 to 19 May 2017

Diabetes · Diabetes Mellitus, Type 2

Trial page ClinicalTrials.govUpdated 15 Oct 2019

CompletedPhase 3Results postedNCT01930188

Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin and/or TZD in Subjects With Type 2 Diabetes

Novo Nordisk A/Sn = 1,2312 Dec 2013 to 12 Oct 2015

Diabetes · Diabetes Mellitus, Type 2

Trial page ClinicalTrials.govUpdated 13 Jun 2019

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:50 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.